KITE-509

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameKITE-509

Drug Alias Nameanti-GPC3 CAR T-cell therapy (Kite)KITE-509

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Source of cells > PMBC-derived +[4]

Mechanisms of ActionGlypican-3 modulatorsT lymphocyte replacements

TargetsGlypican-3

Therapy Area/IndicationsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesKite Pharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesKite Pharma Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A